文献速递肿瘤 PET/CT

利用[18F]FDG PET/CT影像组学预测非小细胞肺癌患者PD-L1表达状态

Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics.
PubMed 文献 · EJNMMI Res · 2023-01-22

本研究回顾性分析2016年9月至2021年7月共334例治疗前接受[18F]FDG PET/CT的非小细胞肺癌患者,提取63个PET和61个CT影像组学特征,构建影像组学模型、临床模型和联合模型。影像组学模型AUC在训练组为0.706、验证组为0.761,均高于临床模型;联合模型AUC分别为0.718和0.769。结论认为PET/CT影像组学特征在预测PD-L1表达状态方面展现出较强潜力,可用于预筛选可能从PD-1/PD-L1免疫治疗中获益的患者。

要点

  • 影像组学模型AUC训练组0.706、验证组0.761,均高于临床模型(0.638、0.640)。
  • 联合模型AUC训练组0.718、验证组0.769。
  • 多因素分析显示临床分期是不同的PD-L1表达状态的显著预测因素(OR 1.579,95%CI 0.220-0.703,P<0.001)。

核心结论

  • 基于PET/CT的影像组学特征在预测PD-L1表达状态方面展现出较强潜力,可用于预筛选可能从PD-1/PD-L1免疫治疗中获益的患者。

研究设计与样本

  • 回顾性分析2016年9月至2021年7月共334例治疗前接受[18F]FDG PET/CT的非小细胞肺癌患者,随机分为训练组(n=233)和验证组(n=101)。
  • 使用LIFEx7.0.0软件包提取63个PET和61个CT影像组学特征,在训练组采用LASSO回归筛选特征,构建并验证影像组学模型、临床模型和联合模型,基于最优模型建立影像组学列线图。

主要发现

  • 共筛选出2个影像组学特征构建影像组学标签模型。
  • 多因素分析显示临床分期是不同的PD-L1表达状态的显著预测因素(OR 1.579,95%CI 0.220-0.703,P<0.001)。
  • 影像组学模型AUC在训练组为0.706、验证组为0.761,均高于临床模型(训练组0.638、验证组0.640)。
  • 联合模型AUC在训练组为0.718、验证组为0.769。

临床怎么用

  • 作者认为PET/CT影像组学特征可用于预筛选可能从PD-1/PD-L1免疫治疗中获益的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In recent years, immune checkpoint inhibitor (ICI) therapy has greatly changed the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the available ICI therapy strategies, programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors are the most widely used worldwide. At present, immunohistochemistry (IHC) is the main method to detect PD-L1 expression levels in clinical practice. However, given that IHC is invasive and cannot reflect the expression of PD-L1 dynamically and in real time, it is of great clinical significance to develop a new noninvasive, accurate radiomics method to evaluate PD-L1 expression levels and predict and filter patients who will benefit from immunotherapy. Therefore, the aim of our study was to assess the predictive power of pretherapy [18F]-fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT)-based radiomics features for PD-L1 expression status in patients with NSCLC. METHODS: A total of 334 patients with NSCLC who underwent [18F]FDG PET/CT imaging prior to treatment were analyzed retrospectively from September 2016 to July 2021. The LIFEx7.0.0 package was applied to extract 63 PET and 61 CT radiomics features. In the training group, the least absolute shrinkage and selection operator (LASSO) regression model was employed to select the most predictive radiomics features. We constructed and validated a radiomics model, clinical model and combined model. Receiver operating characteristic (ROC) curves and the area under the ROC curve (AUC) were used to evaluate the predictive performance of the three models in the training group and validation group. In addition, a radiomics nomogram to predict PD-L1 expression status was established based on the optimal predictive model. RESULTS: Patients were randomly assigned to a training group (n = 233) and a validation group (n = 101). Two radiomics features were selected to construct the radiomics signature model. Multivariate analysis showed that the clinical stage (odds ratio [OR] 1.579, 95% confidence interval [CI] 0.220-0.703, P < 0.001) was a significant predictor of different PD-L1 expression statuses. The AUC of the radiomics model was higher than that of the clinical model in the training group (0.706 vs. 0.638) and the validation group (0.761 vs. 0.640). The AUCs in the training group and validation group of the combined model were 0.718 and 0.769, respectively. CONCLUSION: PET/CT-based radiomics features demonstrated strong potential in predicting PD-L1 expression status and thus could be used to preselect patients who may benefit from PD-1/PD-L1-based immunotherapy.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Zhao X, Zhao Y, Zhang J, et al. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics. EJNMMI Res. 2023. PMID: 36682020. doi:10.1186/s13550-023-00956-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。